Dolutegravir Based Regimens

  • Congress Data

    The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1

    The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1

    GEMINI-1 and GEMINI-2 Studies
    Michael Aboud, VP, Global Medical Lead, Dolutegravir

    The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1

    GEMINI-1 and GEMINI-2 Studies
    Michael Aboud, VP, Global Medical Lead, Dolutegravir
    DTG/3TC: Real-World Evidence

    DTG/3TC: Real-World Evidence

    An Update from CROI 2020
    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    DTG/3TC: Real-World Evidence

    An Update from CROI 2020
    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    DTG: Metabolic Data Update

    DTG: Metabolic Data Update

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    DTG: Metabolic Data Update

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

    Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

    Mark Underwood, Clinical Virologist and Development Investigator

    Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

    Mark Underwood, Clinical Virologist and Development Investigator
    TANGO Study: Metabolic Substudy

    TANGO Study: Metabolic Substudy

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    TANGO Study: Metabolic Substudy

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    DTG+3TC: GEMINI 144-Week Data

    DTG+3TC: GEMINI 144-Week Data

    An Update from HIV GLASGOW 2020
    Nneka Nwokolo, Senior Global Medical Director

    DTG+3TC: GEMINI 144-Week Data

    An Update from HIV GLASGOW 2020
    Nneka Nwokolo, Senior Global Medical Director
    DTG+3TC: TANGO 96-Week Data

    DTG+3TC: TANGO 96-Week Data

    An Update from HIV GLASGOW 2020
    Jose Gatell, Senior Global Medical Director

    DTG+3TC: TANGO 96-Week Data

    An Update from HIV GLASGOW 2020
    Jose Gatell, Senior Global Medical Director
    DTG/3TC: Barrier to Resistance

    DTG/3TC: Barrier to Resistance

    Jan van Lunzen, Head of Translational Medical Research

    DTG/3TC: Barrier to Resistance

    Jan van Lunzen, Head of Translational Medical Research
    Post-CROI 2021 Webinar

    Post-CROI 2021 Webinar

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs

    Post-CROI 2021 Webinar

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs
    GEMINI 144 Week: Efficacy and Safety

    GEMINI 144 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    GEMINI 144 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    TANGO 96 Week: Efficacy and Safety

    TANGO 96 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    TANGO 96 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    GEMINI 48 Week: Adherence Analysis

    GEMINI 48 Week: Adherence Analysis

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    GEMINI 48 Week: Adherence Analysis

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    STAT 24 Week: Feasibility, Efficacy and Safety

    STAT 24 Week: Feasibility, Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    STAT 24 Week: Feasibility, Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
  • Clinical Trials Data

    The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1

    The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1

    GEMINI-1 and GEMINI-2 Studies
    Michael Aboud, VP, Global Medical Lead, Dolutegravir

    The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1

    GEMINI-1 and GEMINI-2 Studies
    Michael Aboud, VP, Global Medical Lead, Dolutegravir
    Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

    Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

    Mark Underwood, Clinical Virologist and Development Investigator

    Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

    Mark Underwood, Clinical Virologist and Development Investigator
    TANGO Study: Metabolic Substudy

    TANGO Study: Metabolic Substudy

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    TANGO Study: Metabolic Substudy

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting

    STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs

    STAT Study: The Feasibility, Efficacy and Safety of Dovato in a Test-and-Treat Setting

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs
    DTG+3TC: GEMINI 144-Week Data

    DTG+3TC: GEMINI 144-Week Data

    An Update from HIV GLASGOW 2020
    Nneka Nwokolo, Senior Global Medical Director

    DTG+3TC: GEMINI 144-Week Data

    An Update from HIV GLASGOW 2020
    Nneka Nwokolo, Senior Global Medical Director
    DTG+3TC: TANGO 96-Week Data

    DTG+3TC: TANGO 96-Week Data

    An Update from HIV GLASGOW 2020
    Jose Gatell, Senior Global Medical Director

    DTG+3TC: TANGO 96-Week Data

    An Update from HIV GLASGOW 2020
    Jose Gatell, Senior Global Medical Director
    Post-CROI 2021 Webinar

    Post-CROI 2021 Webinar

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs

    Post-CROI 2021 Webinar

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs
    GEMINI 144 Week: Efficacy and Safety

    GEMINI 144 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    GEMINI 144 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    TANGO 96 Week: Efficacy and Safety

    TANGO 96 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    TANGO 96 Week: Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    GEMINI 48 Week: Adherence Analysis

    GEMINI 48 Week: Adherence Analysis

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    GEMINI 48 Week: Adherence Analysis

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    STAT 24 Week: Feasibility, Efficacy and Safety

    STAT 24 Week: Feasibility, Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    STAT 24 Week: Feasibility, Efficacy and Safety

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
  • Dosing

    Tivicay PD: An Option for Children Living with HIV

    Tivicay PD: An Option for Children Living with HIV

    Ana M. Puga, MD, Regional Medical Director

    Tivicay PD: An Option for Children Living with HIV

    Ana M. Puga, MD, Regional Medical Director
  • Pharmacokinetics

    Tivicay PD: An Option for Children Living with HIV

    Tivicay PD: An Option for Children Living with HIV

    Ana M. Puga, MD, Regional Medical Director

    Tivicay PD: An Option for Children Living with HIV

    Ana M. Puga, MD, Regional Medical Director
  • Safety

    Post-CROI 2021 Webinar

    Post-CROI 2021 Webinar

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs

    Post-CROI 2021 Webinar

    Andrew Zolopa, MD, VP, Head, North America Medical Affairs
    DTG: Metabolic Data Update

    DTG: Metabolic Data Update

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    DTG: Metabolic Data Update

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    TANGO Study: Metabolic Substudy

    TANGO Study: Metabolic Substudy

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    TANGO Study: Metabolic Substudy

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
    Antiretroviral Therapy and Weight Gain

    Antiretroviral Therapy and Weight Gain

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    Antiretroviral Therapy and Weight Gain

    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
  • Virology/Resistance

    Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

    Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

    Mark Underwood, Clinical Virologist and Development Investigator

    Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

    Mark Underwood, Clinical Virologist and Development Investigator
    DTG/3TC: Barrier to Resistance

    DTG/3TC: Barrier to Resistance

    Jan van Lunzen, Head of Translational Medical Research

    DTG/3TC: Barrier to Resistance

    Jan van Lunzen, Head of Translational Medical Research
  • Real World Evidence

    Dovato Real World Evidence Video

    Dovato Real World Evidence Video

    Dr. Benjamin Young, Head of Global Medical Directors

    Dovato Real World Evidence Video

    Dr. Benjamin Young, Head of Global Medical Directors
    DTG/3TC: Real-World Evidence

    DTG/3TC: Real-World Evidence

    An Update from CROI 2020
    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    DTG/3TC: Real-World Evidence

    An Update from CROI 2020
    Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir